A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk Meeting Abstract


Authors: Choueiri, T. K.; Albiges, L.; Powles, T.; Scheffold, C.; Wang, F.; Motzer, R. J.
Abstract Title: A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk
Meeting Title: 2020 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 38
Issue: 6 Suppl.
Meeting Dates: 2020 Feb 13-15
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2020-02-20
Language: English
ACCESSION: WOS:000529525900070
PROVIDER: wos
DOI: 10.1200/JCO.2020.38.6_suppl.TPS767
Notes: Meeting Abstract: TPS767 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer